The narrowing of Mylan's antitrust claims reduces the expected value of the litigation for VTRS. The case continues but with weaker prospects; monitor for summary judgment motions or settlement developments. TEVA benefits from the dismissal of several theories.
VTRS drugs
VTRS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $13.91entry
- T+1 · 7mo ago −0.36%α −1.15% · $13.86
- T+5 · 7mo ago +5.89%α +4.51% · $14.73
- T+20 · 6mo ago +23.44%α +17.14% · $17.17
- T+60 · 4mo ago +16.97%α +8.26% · $16.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The district court partially granted Teva's motion to dismiss Mylan's antitrust complaint, dismissing with prejudice allegations regarding sham citizen petitions, ANDA lawsuits, market shift, copay assistance, and foreign conduct, but allowing claims based on the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition to proceed. The ruling significantly narrows Viatris's (Mylan's) antitrust case against Teva, reducing the potential scope of damages.
Court Ruling Details
Key Facts
- Court adopted Special Master's R&R, partially granting Teva's motion to dismiss.
- Antitrust allegations regarding 20mg citizen petitions, 20mg ANDA litigation, market shift, copay assistance, and foreign conduct dismissed with prejudice.
- Allegations about DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit survive.
- Lanham Act claim (Count II) and state law claims (Counts III-VI) survive.
- No damages awarded; case proceeds on a narrower set of theories.
- Opinion dated April 13, 2026.
Financial Impact
Mylan's antitrust case against Teva survives but with reduced scope; potential treble damages now limited to surviving claims (DAW campaign, PBM agreements, 2020 reclassification). No dollar amount stated in ruling.
Risk Factors
- Case may be further narrowed on summary judgment or at trial.
- Mylan may settle on less favorable terms given reduced claims.
- Appeal of dismissed claims is unlikely given interlocutory nature of ruling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-15mpe8hi-VTRS |
Track record
22 reports on VTRS
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +16.85% at T+60 after the Aug 6, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers